Novocure Announces Results From Phase 2 PANOVA-4 Trial Of TTFields Therapy Concomitant With Atezolizumab, Gem/Nab-Pac As First-Line Treatment For mPDAC

Novocure (NASDAQ: NVCR) reported positive results from its Phase 2 PANOVA-4 trial, which tested Tumor Treating Fields (TTFields) therapy alongside atezolizumab and gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (mPDAC). The trial met its primary endpoint, showing a disease control rate (DCR) of 74.4% in the treatment group (N=78), significantly higher than the 48% DCR in the historical control group (N=431) from the Phase 3 MPACT study, with a difference of 26.4% and a p-value of less than 0.001.